Oxurion plans to acquire an international CRO

Oxurion NV, a biopharmaceutical company based in Leuven, Belgium, has signed a letter of intent to acquire a majority stake in an international CRO. The target company operates in Europe, North Africa, and the Middle East. This acquisition aims to strengthen Oxurion's integrated model dedicated to clinical development.

The targeted CRO is independent and recognized for its Phase I to IV clinical trials. In 2025, it generated €3 million in revenue, having executed over 300 projects since its inception. The company anticipates 12% growth over three years. Oxurion aims to acquire 75% of its share capital, valuing it at €3,712,500.

The financing will include cash and Oxurion shares. Due diligence will begin in March 2026. The transaction requires the agreement of the parties and compliance with legal requirements. Oxurion has exclusivity until June 30, 2026.